Trial Profile

Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Antiandrogens; LHRH receptor agonists
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

Most Recent Events

10 Oct 2020 This trial has been discontinued in Poland (Date of the global end of the trial: 17 July 2020).
11 Sep 2020 This trial has been Discontinued in Belgium,according to European Clinical Trials Database record.
13 Aug 2020 Status changed from not yet recruiting to withdrawn prior to enrolment withdrawn prior to enrolment as extended study timelines and additional budget could no longer be supported

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com